AKT pathway genes define 5 prognostic subgroups in glioblastoma

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Joy, Anna ^a   Ramesh, Archana ^b   Smirnov, Ivan ^c   Reiser, Mark ^d   Misra, Anjan ^a   Shapiro, William R ^a   Mills, Gordon B ^e   Kim, Seungchan ^f   Feuerstein, Burt G ^a,g  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AKT GENE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; DRUG SENSITIVITY; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; PREDICTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; FEMALE; GENETIC DATABASE; GENETICS; MALE; METABOLISM; MORTALITY;

DATABASES, GENETIC; FEMALE; GLIOBLASTOMA; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL RATE; TOR SERINE-THREONINE KINASES;

EID: 84903701720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100827     Document Type: Article

References (56)

1. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. The American journal of pathology 170: 1445-1453. (Pubitemid 47339290)
2. DeAngelis LM, Mellinghoff IK (2011) Virchow 2011 or how to ID(H) human glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 4473-4474.
3. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, et al. (2005) Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65: 1678-1686. (Pubitemid 40478592)
4. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer cell 9: 157-173. (Pubitemid 43357943)
5. Atlas TCG (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
6. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, et al. (2009) A network model of a cooperative genetic landscape in brain tumors. Jama 302: 261-275.
7. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, et al. (2003) Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22: 2361-2373. (Pubitemid 36566791)
8. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell 17: 510-522.
9. Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB, et al. (2012) Integrative subtype discovery in glioblastoma using iCluster. PLoS ONE 7: e35236.
10. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
11. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, et al. (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4: e7752.
12. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature reviews Cancer 9: 550-562.
13. Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK (2012) Current clinical development of PI3K pathway inhibitors in glioblastoma. Neurooncology 14: 819-829.
14. Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS (2009) Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 6: 500-512.
15. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, et al. (2001) Regulation of PTEN transcription by p53. Molecular cell 8: 317-325. (Pubitemid 32831549)
16. Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, et al. (2002) p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes & development 16: 984-993. (Pubitemid 34408547)
17. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M (2002) Regulation of Raf-Akt Cross-talk. The Journal of biological chemistry 277: 31099-31106. (Pubitemid 34970815)
18. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940. (Pubitemid 46474636)
19. Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, et al. (2007) Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26: 5655-5661. (Pubitemid 47267835)
20. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274. (Pubitemid 46962095)
21. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer research 64: 6503-6510. (Pubitemid 39297907)
22. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
23. Alfarano C, Andrade CE, Anthony K, Bahroos N, Bajec M, et al. (2005) The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Research 33: D418-424. (Pubitemid 40207907)
24. Rafael. A. Irizarry BMB, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research 31: e15.
25. Monti S TP, Mesirov J, Golub T (2003) Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Machine Learning 52: 91-118.
26. Rousseeuw P (1987) Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. Journal of Computational and Applied Mathematics 20: 53-65.
27. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012.
28. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, et al. (2011) Integrative genomics viewer. Nature biotechnology 29: 24-26.
29. Misra A, Pellarin M, Nigro J, Smirnov I, Moore D, et al. (2005) Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 11: 2907-2918. (Pubitemid 40525192)
30. Dunnett CW (1955) A multiple comparison procedure for comparing several treatments with a control. Journal of the American Statistical Association 50: 1096-1121.
31. Kutner MH, Nachtsheim C, Neter J, Li W (2005) Applied Linear Statistical Models. New York: McGraw-Hill.
32. The Cancer Genome Atlas NCI, National Institutes of Health, Bethesda, MD. Available: http://cancergenome.nih.gov/.
33. West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248. (Pubitemid 36132805)
34. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, et al. (2002) Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer research 62: 6205-6210. (Pubitemid 35244472)
35. French PEL, Gravendeel L, Rooi J, Eiler P, Idbaih A, et al. (2012) Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant PCV chemotherapy in anaplastic oligodendroglial brain tumors: A report from the EORTC study 26951Y 26951 Neuro Oncol 14: OM-21.
36. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, et al. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta neuropathologica 116: 597-602.
37. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, et al. (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 11: 341-347.
38. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
39. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
40. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, et al. (2000) A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Molecular endocrinology 14: 783-794. (Pubitemid 32260492)
41. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, et al. (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. The Journal of cell biology 166: 213-223. (Pubitemid 38988774)
42. Efeyan A, Sabatini DM (2010) mTOR and cancer: many loops in one pathway. Current opinion in cell biology 22: 169-176.
43. Hartley D, Cooper GM (2002) Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. Journal of cellular biochemistry 85: 304-314. (Pubitemid 34274898)
44. Huang J, Dibble CC, Matsuzaki M, Manning BD (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Molecular and cellular biology 28: 4104-4115. (Pubitemid 351812994)
45. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH (2005) Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer research 65: 2755-2760. (Pubitemid 40490077)
46. Banerjee S, Crouse NR, Emnett RJ, Gianino SM, Gutmann DH (2011) Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proceedings of the National Academy of Sciences of the United States of America 108: 15996-16001.
47. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, et al. (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proceedings of the National Academy of Sciences of the United States of America 102: 8573-8578. (Pubitemid 40862777)
48. Everitt B (2006) The Cambridge dictionary of statistics. New York: Cambridge University Press.
49. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381-1393. (Pubitemid 27143246)
50. Mittler MA, Walters BC, Stopa EG (1996) Observer reliability in histological grading of astrocytoma stereotactic biopsies. Journal of neurosurgery 85: 1091-1094. (Pubitemid 26396564)
51. Gotz M, Huttner WB (2005) The cell biology of neurogenesis. Nature reviews Molecular cell biology 6: 777-788. (Pubitemid 41726116)
52. Sakai D, Dixon J, Dixon MJ, Trainor PA (2012) Mammalian neurogenesis requires Treacle-Plk1 for precise control of spindle orientation, mitotic progression, and maintenance of neural progenitor cells. PLoS genetics 8: e1002566.
53. Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, Le Belle J, et al. (2006) PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A 103: 111-116. (Pubitemid 43076113)
54. Sinor AD, Lillien L (2004) Akt-1 expression level regulates CNS precursors. J Neurosci 24: 8531-8541. (Pubitemid 39313776)
55. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, et al. (2013) The somatic genomic landscape of glioblastoma. Cell 155: 462-477.
56. Network TCGAR (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.